metformin has been researched along with Neointima in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Neointima: The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We demonstrated that the potential protection of the combined use of linagliptin and metformin on VSMC remodeling through AMPK/Nox4 signal pathway, resulting in the improvement of neointima hyperplasia in diabetic rats." | 7.91 | Inhibition of neointima hyperplasia by the combined therapy of linagliptin and metformin via AMPK/Nox4 signaling in diabetic rats. ( Li, XX; Tai, GJ; Xu, M; Zhang, WX, 2019) |
| "Treatment with metformin significantly attenuates neointimal hyperplasia through inhibition of smooth muscle cell proliferation, migration, and inflammation as well as by improvement of the insulin signaling pathway." | 5.39 | The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats. ( Adeli, K; Ji, J; Jiang, B; Liu, L; Lu, J; Meng, H; Meng, QH; Randell, E; Wang, D, 2013) |
| "We demonstrated that the potential protection of the combined use of linagliptin and metformin on VSMC remodeling through AMPK/Nox4 signal pathway, resulting in the improvement of neointima hyperplasia in diabetic rats." | 3.91 | Inhibition of neointima hyperplasia by the combined therapy of linagliptin and metformin via AMPK/Nox4 signaling in diabetic rats. ( Li, XX; Tai, GJ; Xu, M; Zhang, WX, 2019) |
| "Treatment with metformin significantly attenuates neointimal hyperplasia through inhibition of smooth muscle cell proliferation, migration, and inflammation as well as by improvement of the insulin signaling pathway." | 1.39 | The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats. ( Adeli, K; Ji, J; Jiang, B; Liu, L; Lu, J; Meng, H; Meng, QH; Randell, E; Wang, D, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, WX | 1 |
| Tai, GJ | 1 |
| Li, XX | 1 |
| Xu, M | 1 |
| Lu, J | 1 |
| Ji, J | 1 |
| Meng, H | 1 |
| Wang, D | 1 |
| Jiang, B | 1 |
| Liu, L | 1 |
| Randell, E | 1 |
| Adeli, K | 1 |
| Meng, QH | 1 |
2 other studies available for metformin and Neointima
| Article | Year |
|---|---|
Inhibition of neointima hyperplasia by the combined therapy of linagliptin and metformin via AMPK/Nox4 signaling in diabetic rats.
Topics: AMP-Activated Protein Kinases; Animals; Aorta, Thoracic; Carotid Arteries; Constriction, Pathologic; | 2019 |
The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats.
Topics: Animals; Blood Glucose; Carotid Arteries; Carotid Artery Injuries; Carotid Stenosis; Cells, Cultured | 2013 |